Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.
At the end of the third quarter, the chemical industry continues to face an economic slowdown, compounded by international trade conflicts, increased political uncertainty, and fundamental changes to the value chain (e. g. the case of electro-mobility.)
The consulting business has a new bandwagon: agility or agile management. Should the chemical industry jump on it or should we let it pass by?
Miebach Consulting has launched an international survey in order to evaluate the most relevant challenges and trends for supply chain organizations within the pharma & life sciences industry.
Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025."
Outsourcing product development and manufacturing has become for many pharmaceutical and biotech companies a strategic activity and an integral part of their business model.
